Dr Dean Craig Singleton
Dean Singleton obtained his BSc(Hons) in Biomedical Sciences at the University of Auckland and his PhD in Molecular Medicine and Pathology at the University of Auckland under the supervision of Associate Professor Adam Patterson and Professor Bill Wilson. He then completed a postdoctoral fellowship in the laboratory of Professor Adrian Harris at the Weatherall Institute of Molecular Medicine, University of Oxford, investigating transcriptional responses to tumour hypoxia. In 2014 he joined the laboratory of Dr Susanne Müller-Knapp in the Nuffield Department of Medicine, University of Oxford, developing chemical probes to target epigenetic proteins. In 2015 he was awarded the Rodney and Elaine Davies Cancer Research Fellowship to return to the University of Auckland.
Dr Singleton’s primary interest is in the development of antitumour agents that target tumour hypoxia with a focus on blocking the epigenetic reprogramming implicated in transcriptional responses to hypoxia.
Selected publications and creative works (Research Outputs)
- Liew, L. P., Wong, W. W., Singleton, D. C., Jamieson, S. M., Flanagan, J. F., Koumenis, C., & Hay, M. P. (2017). The Development of Hypoxia-selective PERK Inhibitor Prodrugs. Paper presented at 15th International Tumor Microenvironment Workshop, The Palms Hotel and Spa, Miami Beach, Florida. 27 April - 29 April 2017. Related URL.
Other University of Auckland co-authors: Lydia Liew, Way Wong, Stephen Jamieson, Jack Flanagan, Michael Hay
- McIntyre, A., Hulikova, A., Ledaki, I., Snell, C., Singleton, D., Steers, G., ... Wigfield, S. (2016). Disrupting Hypoxia-Induced Bicarbonate Transport Acidifies Tumor Cells and Suppresses Tumor Growth. Cancer research, 76 (13), 3744-3755. 10.1158/0008-5472.can-15-1862
- Singleton, D. C., Rouhi, P., Zois, C. E., Haider, S., Li, J.-L., Kessler, B. M., ... Harris, A. L. (2015). Hypoxic regulation of RIOK3 is a major mechanism for cancer cell invasion and metastasis. Oncogene, 34 (36), 4713-4722. 10.1038/onc.2014.396
- Clark, P. G. K., Vieira, L. C. C., Tallant, C., Fedorov, O., Singleton, D. C., Rogers, C. M., ... Müller S (2015). LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor. Angewandte Chemie (Weinheim an der Bergstrasse, Germany), 127 (21), 6315-6319. 10.1002/ange.201501394
- Clark, P. G. K., Vieira, L. C. C., Tallant, C., Fedorov, O., Singleton, D. C., Rogers, C. M., ... Müller S (2015). LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor. Angewandte Chemie (International ed. in English), 54 (21), 6217-6221. 10.1002/anie.201501394
- Pettersen, E. O., Ebbesen, P., Gieling, R. G., Williams, K. J., Dubois, L., Lambin, P., ... Langdon, S. P. (2015). Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. Journal of enzyme inhibition and medicinal chemistry, 30 (5), 689-721. 10.3109/14756366.2014.966704
- Hay, D. A., Fedorov, O., Martin, S., Singleton, D. C., Tallant, C., Wells, C., ... Rogers, C. M. (2014). Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. Journal of the American Chemical Society, 136 (26), 9308-9319. 10.1021/ja412434f
- Harris, A. L., Buffa, F. M., Haider, S., Bensaad, K., McIntyre, A., Lord, S., ... Ledaki, I. (2013). Abstract BS02-1: Hypoxia metabolism in breast cancer – How to overcome resistance to anti-angiogenic therapy. Cancer Research, 73 (24 Supplement), BS02-1-BS02-1. 10.1158/0008-5472.SABCS13-BS02-1